Financial Performance - The unaudited revenue of RMH Holdings Limited for the nine months ended 30 September 2022 was approximately S$11,436,000, representing an increase of approximately S$3,945,000 or 52.7% compared to S$7,491,000 for the same period in 2021[8][11]. - The unaudited loss for the Group was approximately S$5,887,000 for the nine months ended 30 September 2022, an increase of approximately S$1,716,000 or 41.1% from the loss of S$4,171,000 for the same period in 2021[9][11]. - The total comprehensive loss for the previous period (nine months ended September 30, 2021) was S$4,268,000[16]. - The company reported a loss before taxation of S$5,887,000 for the nine months ended September 30, 2022, compared to a loss of S$4,115,000 in the previous year, reflecting an increase in losses of 43.1%[78]. - The loss per share for the nine months ended 30 September 2022 was S$0.50, compared to S$0.58 for the same period in 2021[10][13]. Revenue Breakdown - Revenue from Aesthetic Services was S$820,000, up 105.3% from S$399,000 in the previous year[72]. - Revenue from Consultation Services increased to S$1,660,000, a rise of 12.9% from S$1,470,000 in 2021[72]. - Prescription and Dispensing Services generated S$2,783,000, compared to S$2,181,000, reflecting a growth of 27.6%[72]. - Treatment Services revenue rose to S$2,398,000, an increase of 13.3% from S$2,116,000 in the prior year[72]. - Trading Sales surged to S$2,420,000, significantly up from S$209,000, marking a growth of 1,055.0%[72]. - Other Services, primarily from laboratory tests, contributed S$1,355,000, an increase from S$1,116,000, representing a growth of 21.4%[72]. Expenses and Costs - Employee benefits expense was approximately S$6,381,000, which increased by approximately S$2,185,000 or 52.1% compared to the previous year, primarily due to additional headcounts at the Hong Kong office[9][11]. - Other operating expenses increased due to derecognition of finance lease receivables and miscellaneous expenses[9][11]. - Total consumables and medical supplies used amounted to approximately S$3,726,000 for the nine months ended 30 September 2022, up from approximately S$1,342,000 in 2021, reflecting increased service demand[116]. - Other operating expenses increased by approximately S$1,427,000 or 35.8% from approximately S$3,986,000 for the nine months ended 30 September 2021 to approximately S$5,413,000 for the nine months ended 30 September 2022[131]. Share Capital and Dividends - The Board did not recommend the payment of any dividend for the nine months ended 30 September 2022[10]. - As of September 30, 2022, the total share capital increased to S$2,240,000 from S$1,483,000 at the beginning of the year[16]. - The company issued shares by placing, raising a total of S$7,469,000 during the period[16]. - The retained earnings as of September 30, 2022, showed a deficit of S$21,970,000, compared to a deficit of S$16,084,000 at the beginning of the year[16]. Corporate Governance - The company has adopted the Corporate Governance Code as its own code of corporate governance[170]. - The company is committed to high standards of corporate governance to manage business risks and enhance transparency[170]. - The company has independent non-executive directors forming the majority of the board, ensuring a balance of power[173]. - The company will continue to review and improve its corporate governance practices[170]. Market Outlook - The Group is cautiously optimistic about a strong rebound in performance for the year 2022, driven by the easing of government anti-COVID-19 measures and the ongoing mass vaccination rollout[105]. - The Group's overall financial position will be closely monitored to evaluate the potential impact of ongoing market conditions[105].
德斯控股(08437) - 2022 Q3 - 季度财报